Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

NCT02875132 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Acral Lentiginous Melanoma

Interventions

DRUG: pembrolizumab

Sponsor

Chinese University of Hong Kong